Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.

Journal of the National Cancer Institute - 19 Mar 2003

Singer Gad, Oldt Robert, Cohen Yoram, Wang Brant G, Sidransky David, Kurman Robert J, Shih Ie-Ming

Abstract excerpt

Activating mutations in KRAS and in one of its downstream mediators, BRAF, have been identified in a variety of human cancers. To determine the role of mutations in BRAF and KRAS in ovarian carcinoma, we analyzed both genes for three common mutations (at codon 599 of BRAF and codons 12 and 13 of KRAS). Mutations in either codon 599 of BRAF or codons 12 and 13 of KRAS occurred in 15 of 22 (68%) invasive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Codon
Share to BRAF gene
Share to KRAS gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, ras

Share to Mutation

Share to Ovarian cancer diagnosis and treatment

Share to Ovarian Neoplasms

Share to Proto-Oncogene Proteins c-raf

Source

Identifiers

PMID: 12644542
DOI: 10.1093/jnci/95.6.484

Genes

BRAF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.PMID 12644542Read ↗

In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.Semantic proximity Read ↗

Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors.Semantic proximity Read ↗

A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes.Semantic proximity Read ↗

Low-grade serous ovarian cancer: A review.Semantic proximity Read ↗

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.Semantic proximity Read ↗

Low‐grade serous carcinomas of the ovary contain very few point mutationsSemantic proximity Read ↗

The molecular pathology of ovarian serous borderline tumors.Semantic proximity Read ↗

Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.Semantic proximity Read ↗

Germ line and somatic mutations of BRAF V599E in ovarian carcinoma.Semantic proximity Read ↗

Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma CellsSemantic proximity Read ↗

Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.Semantic proximity Read ↗

Low frequency of BRAF and KRAS mutations in Chinese patients with low-grade serous carcinoma of the ovary.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.